PTC Therapeutics has shared the results of the dystrophin study (Study 045), which assessed dystrophin levels in patients with nonsense mutation Duchenne muscular dystrophy treated with Translarna™ (ataluren).
Click here to see the full press release.
The Duchenne community is invited to hear more about the study results on their conference call:
When: Thursday, February 11, 2021, at 12:30 p.m. EST
Access by calling (973) 935-8152 (international), passcode 7714859.
If you have any questions prior to the call, please submit them to Defeat Duchenne Canada and we will gladly bring them forward on the call: email@example.com.